Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults with HCV GT1b and ESRD
NCT02806362Phase 3Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Sep 2016
- Primary completion
- Jun 2018
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of ombitasvir, paritaprevir, ritonavir in hepatitis C (HCV), sponsored by AbbVie Inc.. Planned start Sep 2016; status: withdrawn.
02
Drugs
ombitasvirparitaprevirritonavir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02806362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02806362.